PCI completes Korean order

Published: 3-Feb-2001


PCI-Memtech has completed a contract supplying the Korean company Boryung Pharmaceutical with a multipurpose membrane plant. The plant will be used in the production of anticancer treatments.

The filtration unit uses both reverse osmosis and nanofiltration membranes on a single plant and is an integral part of the production process. This process commences with an initial clarification of the fermentation broth by either filter press or decanter. The clarified stream is polished by ultrafiltration and the product molecule is extracted with an alcohol.

Following ion exchange and re-extraction into the aqueous phase, the drug is concentrated in a PCI-Memtech reverse osmosis unit fitted with tubular membranes. This RO process is followed by evaporation and drying to yield the final product. A spiral nanofiltration membrane is used in the recovery of the alcohol from the solvent mother liquor.

You may also like